CSIMarket
 


Eli Lilly And Company  (LLY)
Other Ticker:  
 
 

LLY's Operating Income Growth by Quarter and Year

Eli Lilly And's Operating Income results by quarter and year




LLY Operating Income (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 1,836.40 1,917.20 1,992.10
III Quarter September - 1,676.50 1,881.20 1,278.30
II Quarter June 2,125.70 1,210.10 1,403.40 1,196.80
I Quarter March 1,494.00 2,404.30 1,155.30 1,590.80
FY   3,619.70 7,127.30 6,357.10 6,058.00



LLY Operating Income second quarter 2023 Y/Y Growth Comment
Eli Lilly And Company achieved in the second quarter 2023, above Company average Operating Income rise of 75.66% year on year, to $ 2,125.70 millions.

Looking into second quarter 2023 results within Major Pharmaceutical Preparations industry 12 other companies have achieved higher Operating Income growth. While Eli Lilly And Company' s Operating Income jump of 75.66% ranks overall at the positon no. 1181 in the second quarter 2023.

Explain Operating Income growth


LLY Operating Income ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - -4.21 % -3.76 % 42.27 %
III Quarter September - -10.88 % 47.16 % -10.65 %
II Quarter June 75.66 % -13.77 % 17.26 % -20.12 %
I Quarter March -37.86 % 108.11 % -27.38 % 146.6 %
FY   - 12.12 % 4.94 % 21.79 %

Financial Statements
Eli Lilly And's second quarter 2023 Operating Income $ 2,125.70 millions LLY's Income Statement
Eli Lilly And's second quarter 2022 Operating Income $ 1,210.10 millions Quarterly LLY's Income Statement
New: More LLY's historic Operating Income Growth >>


LLY Operating Income (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - 9.54 % 1.91 % 55.84 %
III Quarter September - 38.54 % 34.05 % 6.81 %
II Quarter June 42.28 % -49.67 % 21.47 % -24.77 %
I Quarter March -18.65 % 25.41 % -42.01 % 13.61 %
FY (Year on Year)   - 12.12 % 4.94 % 21.79 %




Operating Income second quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #13
Healthcare Sector #53
Overall #1181

Operating Income Y/Y Growth Statistics
High Average Low
458.23 % 8.79 % -134.13 %
(Sep. 30. 2010)   (Dec. 31, 2008)
Operating Income second quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #13
Healthcare Sector #53
Overall #1181
Operating Income Y/Y Growth Statistics
High Average Low
458.23 % 8.79 % -134.13 %
(Sep. 30. 2010)   (Dec. 31, 2008)

Operating Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Eli Lilly And's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
2642.73 % 54.03 % -94.74 %
(Jun 30 2017)  


LLY's II. Quarter Q/Q Operating Income Comment
Eli Lilly And Company achieved in the II. Quarter 2023 below company average Operating Income jump of 42.28% quarter on quarter, to $ 2,125.70 millions.

Although the II. Quarter 2023 Eli Lilly And's performance was beneath the average of 54.03 %, this was still promising story, as the II. Quarter expension, eclipses the -49.67% surge in the II. Quarter a year ago

Within Major Pharmaceutical Preparations industry 8 other companies have achieved higher Operating Income quarter on quarter growth. While Eli Lilly And's Operating Income growth quarter on quarter, overall rank is 453.


Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #9
Healthcare Sector #39
Overall #453
Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #9
Healthcare Sector #39
Overall #453
Operating Income Q/Q Growth Statistics
High Average Low
2642.73 % 54.03 % -94.74 %
(Jun 30 2017)  


LLY's II. Quarter Q/Q Operating Income Comment
Eli Lilly And Company achieved in the II. Quarter 2023 below company average Operating Income jump of 42.28% quarter on quarter, to $ 2,125.70 millions.

II. Quarter 2023 Eli Lilly And's Operating Income quarter on quarter growth appear to be paradoxical, even if below the ordinary rise of 54.03 %, yet it shows real recovery relative to the -49.67% in the same quarter a year ago Andrea Stewart, a business advisor situated in San Francisco mentioned.

Within Major Pharmaceutical Preparations industry 8 other companies have achieved higher Operating Income quarter on quarter growth. While Eli Lilly And's Operating Income growth quarter on quarter, overall rank is 453.


Eli Lilly And's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
Cumulative Operating Income 12 Months Ending $ 7,132.60 $ 6,217.00 $ 7,127.30 $ 7,208.10 $ 7,412.80
Y / Y Operating Income Growth (TTM) -3.78 % -18.26 % 12.12 % 12.07 % 27.17 %
Year on Year Operating Income Growth Overall Ranking # 606 # 86 # 992 # 902 # 845
Seqeuential Operating Income Change (TTM) 14.73 % -12.77 % -1.12 % -2.76 % -2.54 %
Seq. Operating Income Growth (TTM) Overall Ranking # 1181 # 769 # 1128 # 1496 # 1592




Cumulative Operating Income growth Comment
Eli Lilly And showed decline, but improvement compare to trailing twelve month Operating Income decrease in Mar 31 2023. If the fiscal year would end in Jun 30 2023, Eli Lilly And's annual Operating Income decline would be -3.78% year on year to $7,133 millions.

Within the Healthcare sector 23 other companies have achieved higher trailing twelve month Operating Income growth. While Operating Income growth total ranking has deteriorated compare to previous quarter from 86 to 606.

Operating Income TTM Q/Q Growth Statistics
High Average Low
458.23 %
8.79 %
-134.13 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 13
Healthcare Sector # 24
Overall # 606

Operating Income TTM Y/Y Growth Statistics
High Average Low
458.23 %
8.79 %
-134.13 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 13
Sector # 53
S&P 500 # 1181
Cumulative Operating Income growth Comment
Eli Lilly And showed decline, but improvement compare to trailing twelve month Operating Income decrease in Mar 31 2023. If the fiscal year would end in Jun 30 2023, Eli Lilly And's annual Operating Income drop would be -3.78% year on year to $7,133 millions.

Within the Healthcare sector 23 other companies have achieved higher trailing twelve month Operating Income growth. While Operating Income growth total ranking has deteriorated compare to previous quarter from 86 to 606.

Operating Income TTM Q/Q Growth Statistics
High Average Low
458.23 %
8.79 %
-134.13 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 13
Healthcare Sector # 24
Overall # 606

Operating Income TTM Y/Y Growth Statistics
High Average Low
458.23 %
8.79 %
-134.13 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 13
Sector # 53
S&P 500 # 1181




Other Operating Income Growth
Major Pharmaceutical Preparations Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
LLY's Operating Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for LLY's Competitors
Operating Income Growth for Eli Lilly And's Suppliers
Operating Income Growth for LLY's Customers

You may also want to know
LLY's Annual Growth Rates LLY's Profitability Ratios LLY's Asset Turnover Ratio LLY's Dividend Growth
LLY's Roe LLY's Valuation Ratios LLY's Financial Strength Ratios LLY's Dividend Payout Ratio
LLY's Roa LLY's Inventory Turnover Ratio LLY's Growth Rates LLY's Dividend Comparisons



Companies with similar Operating Income drop for the quarter ending Jun 30 2023 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Jun 30 2023
Community Health Systems Inc 106.72%$ 106.723 millions
Lantheus Holdings Inc 96.41%$ 96.410 millions
Cadre Holdings inc 94.78%$ 94.777 millions
Jazz Pharmaceuticals Plc84.27%$ 84.270 millions
Inotiv Inc 83.48%$ 83.476 millions
Eli Lilly And Company75.66%$ 75.663 millions
Lifevantage Corp73.93%$ 73.930 millions
Progyny Inc 71.80%$ 71.804 millions
Artivion Inc 69.02%$ 69.016 millions
Dexcom Inc 66.36%$ 66.364 millions
Idexx Laboratories Inc65.38%$ 65.383 millions
Catalyst Pharmaceuticals Inc 63.46%$ 63.460 millions
Lemaitre Vascular Inc 63.42%$ 63.416 millions
Horizon Therapeutics Public Limited Company61.30%$ 61.298 millions
Elite Pharmaceuticals Inc 56.65%$ 56.649 millions
United Therapeutics Corporation55.30%$ 55.302 millions
Msa Safety Inc54.39%$ 54.394 millions
Biomarin Pharmaceutical Inc50.36%$ 50.363 millions
Amphastar Pharmaceuticals Inc 48.64%$ 48.636 millions
Murphy Canyon Acquisition Corp 45.40%$ 45.396 millions
Harmony Biosciences Holdings inc 41.63%$ 41.629 millions
Ufp Technologies Inc39.70%$ 39.700 millions
Option Care Health Inc 39.43%$ 39.425 millions
Harrow Health Inc 39.17%$ 39.172 millions
Semler Scientific inc 38.66%$ 38.664 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com